ERBB3 and neoplasm: We compared HerOND with the HER2 antibody Tz for in vivo tumour-homing capacity after systemic delivery in mice bearing peripheral HER2 + JIMT-1 human breast tumours which display both HER2 and HER3 (Supplementary Fig. 14) and inherently resist Tz37.